BPG is committed to discovery and dissemination of knowledge
Systematic Reviews
Copyright: ©Author(s) 2026.
World J Clin Oncol. Aug 24, 2026; 17(8): 123094
Published online Aug 24, 2026. doi: 10.5306/wjco.123094
Table 2 Segment-specific station-level interpretation for multidisciplinary planning
Tumor segment
Dominant signal
Supporting evidence
Practical interpretation
Upper thoracic SCCEUpper mediastinal and recurrent laryngeal nerve involvement; CHiSCEC high-risk stations No. 105, No. 106recR, and No. 106recLLiu et al[9]; CHiSCEC[13]; Jiao et al[10]upper mediastinal nodal assessment should be explicit; lower mediastinal assessment remains warranted when imaging, tumor length, or pathology suggests risk
Middle thoracic SCCEMost diffuse pattern, including upper and middle mediastinal, recurrent nerve, perigastric, and abdominal compartments; CHiSCEC high-risk stations No.107, No. 108, and abdominal No. 7Liu et al[9]; CHiSCEC[13]; Wu et al[11]Bidirectional nodal evaluation is more defensible than a narrow peritumoral field
Lower thoracic SCCEDominant lower mediastinal, perigastric, and abdominal signal; CHiSCEC high-risk stations No. 107, No. 110, abdominal No. 2, and abdominal No. 7Liu et al[9]; CHiSCEC[13]Upper abdominal and perigastric risk should be weighed against operative and radiotherapy morbidity; upper mediastinal skip risk remains possible
Cross-segment issueSkip metastasis and named station risk are clinically relevant but not yet independently linked to survivalLiu et al[9]; Xu et al[8]; CHiSCEC[13]Standardized station reporting is needed before classical efficacy-index or station-specific survival claims can be made


Write to the Help Desk